Toth Financial Advisory Corp Vertex Pharmaceuticals Inc Transaction History

Toth Financial Advisory Corp

$825 Million
Q3 2024

A detailed history of Toth Financial Advisory Corp transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Toth Financial Advisory Corp holds 1,550 shares of VRTX stock, worth $615,768. This represents 0.09% of its overall portfolio holdings.

Number of Shares

1,550

Previous 100 1450.0%

Holding current value

$615,768

Previous $46,000 1465.22%

% of portfolio

0.09%

Previous 0.01%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 21, 2024	BUY	$460.0 - $505.78 $667,000 - $733,381	1,450 Added 1450.0%	1,550 $720,000
Q2 2023 Jul 24, 2023	SELL	$314.42 - $351.91 $12,262 - $13,724	-39 Reduced 28.06%	100 $35,000
Q1 2023 Apr 24, 2023	BUY	$283.23 - $323.1 $11,045 - $12,600	39 Added 39.0%	139 $43,000
Q4 2021 Jan 31, 2022	BUY	$177.01 - $223.45 $14,514 - $18,322	82 Added 455.56%	100 $22,000
Q4 2020 Jan 25, 2021	SELL	$207.01 - $276.09 $595,153 - $793,758	-2,875 Reduced 99.38%	18 $4,000
Q3 2020 Oct 16, 2020	SELL	$255.65 - $303.1 $411,596 - $487,991	-1,610 Reduced 35.75%	2,893 $787,000
Q2 2020 Jul 14, 2020	BUY	$225.48 - $295.8 $99,887 - $131,039	443 Added 10.91%	4,503 $1.31 Million
Q1 2020 Apr 20, 2020	BUY	$199.77 - $247.81 $265,694 - $329,587	1,330 Added 48.72%	4,060 $966,000
Q4 2019 Jan 27, 2020	BUY	$166.71 - $223.91 $455,118 - $611,274	2,730 New	2,730 $598,000
Q2 2019 Jul 17, 2019	SELL	$164.61 - $190.37 $270,289 - $312,587	-1,642 Closed	0 $0
Q1 2019 Apr 15, 2019	BUY	$163.73 - $194.7 $268,844 - $319,697	1,642 New	1,642 $302,000

Others Institutions Holding VRTX

# of Institutions

1,724

Shares Held

221M

Call Options Held

1.58M

Put Options Held

1.36M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $102B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Toth Financial Advisory Corp, based on Form 13F filings with the SEC.

News

Stay updated on Toth Financial Advisory Corp with notifications on news.

Account

Toth Financial Advisory Corp Vertex Pharmaceuticals Inc Transaction History